Updated:
Flagship Biosciences
Flagship Biosciences is a data-centric pathology services company based in Flagstaff, United States, founded in 2009. The company has secured $20.9 million in...
Flagship Biosciences
Flagship Biosciences is a data-centric pathology services company based in Flagstaff, United States, founded in 2009. The company has secured $20.9 million in total funding.
General information
Firm type
other
Year founded
2009
Location
Region
North America
Country
United States
City
Broomfield
Corporate office
Broomfield, CO, United States
Principals
Thomas Turi
Ph.D. (Leadership)
Boaz Kurtis
MD (Leadership)
Ken H Young
Dr. (Leadership)
Lenka Sinik
Ph.D. (Leadership)
Parker W Clement
MD (Leadership)
Sector focus
Frequently asked questions
Who runs Flagship Biosciences?
Thomas Turi, Ph.D., is a named leader, along with Boaz Kurtis, MD, Dr. Ken H Young, Lenka Sinik, Ph.D., and Parker W Clement, MD. No CEO or managing director is explicitly titled on the firm's website.
Is Flagship Biosciences a family office or investment firm?
No. Flagship Biosciences is a CLIA-certified and CAP-accredited laboratory services company focused on spatial biology and biomarker analysis, not an investment vehicle.
What services does Flagship Biosciences offer?
The firm provides spatial biology (IHC to digital spatial profiling), genomics (high-throughput NGS and targeted gene panels), and histopathology with AI-powered analysis for clinical trials and drug development.
Who are Flagship Biosciences' typical clients?
Clients include pharmaceutical companies, biotech firms, neuro-oncology research laboratories, and diagnostic providers. The firm supports both clinical-stage drug development and translational research.
Does Flagship Biosciences have any regulatory certifications?
Yes, the laboratory is CLIA-Certified and CAP-Accredited, which qualifies it to support clinical trial biomarker analysis.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: